Tag Archives: bmy

Bristol’s Opdivo Scores Again Against Lung Cancer

Big pharma Bristol-Myers Squibb’s (BMY) cancer drug Opdivo continued to shine Friday, as the company halted another clinical trial early because it had already hit its endpoint. The phase-three trial, called Checkpoint-057, compared Opdivo in advanced non-squamous non-small-cell lung cancer with standard treatment docetaxel (better known as Sanofi’s (SNY) Taxotere). The study found a significant improvement in overall survival in the Opdivo arm,

Bristol-Myers, UniQure To Team Up On Heart Disease

Bristol-Myers Squibb (BMY) announced Monday it acquired an initial equity stake in UniQure (QURE) as part of a partnership on gene therapies for heart disease. The drug giant is paying $33.83 per share for the stake, above Thursday’s closing price of $22.86, as well as an upfront payment of $50 million. Bristol-Myers will buy another 5% stake by the end of this year and be given warrants to buy up to another 10% stake in the company. The parties

Merck’s Keytruda Bests Yervoy In Early Melanoma

Big pharma Merck (MRK) said Tuesday that it will stop a phase-three trial of cancer drug Keytruda for melanoma because the trial had already met its goals ahead of schedule. Merck’s stock rose about 1% in early trading. The trial, called Keynote-006, compared Keytruda head to head with Bristol-Myers Squibb’s (BMY) Yervoy, currently the standard of care for melanoma, in previously untreated patients. Merck said that the trial had met its endpoints